PROGRAM PLANNING COMMITTEE

William C. Eckelman
David M. Goldenberg (Chairman)
Edgar Haber
Thomas Hoffman
Steven M. Larson
Stanley E. Order
Howard Sands
Mette Strand

PROGRAM

Introduction to the Second Conference on Radioimmunodetection and Radioimmunotherapy of Cancer.
David M. Goldenberg ................................................................. 778s

SESSION I

Radiochemistry of Antibodies

Chairperson: William C. Eckelman

Development of Radiochemically Pure Antibodies.
W. C. Eckelman ................................................................. 780s

Improving the Tumor Retention of Radioiodinated Antibody: Aryl Carbohydrate Adducts.

Stable Bifunctional Chelates of Metals Used in Radiotherapy.
Min K. Moi, Sally J. DeNardo, and Claude F. Meares ......................................................... 789s

Preclinical Evaluation of an "Instant" 99mTc-labeling Kit for Antibody Imaging.
Hans J. Hansen, Anastasia L. Jones, Robert M. Sharkey, Ruth Grebenau, Nancy Blazejewski, Arthur Kunz, Michael J. Buckley, Edward S. Newman, Frank Ostella, and David M. Goldenberg ......................................................... 794s

99mTc Labeling of Proteins: Initial Evaluation of a Novel Diaminedithiol Bifunctional Chelating Agent.
Kwamena E. Baidoo, Ursula Scheffel, and Susan Z. Lever ......................................................... 799s

Disulfide Bond-targeted Radiolabeling: Tumor Specificity of a Streptavidin-biotinylated Monoclonal Antibody Complex.
Renato B. del Rosario and Richard L. Wahl ......................................................... 804s

SESSION II

Experimental Studies of Radioimmunodetection

Chairpersons: Howard Sands and Jeffrey Schlom

Experimental Studies of Radioimmunodetection of Cancer: An Overview.
Howard Sands ................................................................. 809s

Physiological Barriers to Delivery of Monoclonal Antibodies and Other Macromolecules in Tumors.
Rakesh K. Jain ................................................................. 814s

Innovations That Influence the Pharmacology of Monoclonal Antibody Guided Tumor Targeting.
Jeffrey Schlom, Patricia Horan Hand, John W. Greiner, David Colcher, Shashi Shrivastav, Jorge A. Carrasquillo, James C. Reynolds, Steven M. Larson, and Andrew Raubitschek ......................................................... 820s

Comparison of Tumor Targeting in Nude Mice by Murine Monoclonal Antibodies Directed against Different Human Colorectal Cancer Antigens.
Robert M. Sharkey, David V. Gold, Rosarito Aninipot, Rae Vagg, Cathy Ballance, Edward S. Newman, Frank Ostella, Hans J. Hansen, and David M. Goldenberg ......................................................... 828s

Pharmacokinetics of 99mTc-Metallothionein-B72.3 and Its F(ab')2 Fragment.
Beverly A. Brown, Cynthia B. Dearborn, Cynthia A. Drozynski, and Howard Sands ......................................................... 835s

Mechanisms of Tissue Uptake and Metabolism of Radiolabeled Antibody—Role of Antibigen: Antibody Complex Formation.
J. David Beatty, Barbara G. Beatty, Margaret O'Conner-Tressel, Tulan Do, and Raymond J. Paxton ......................................................... 840s
Mechanism of Decreasing Liver Uptake of $^{111}$In-labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody by Specific Antibody Pretreatment in Tumor Bearing Mice.
Barbara G. Beatty, Margaret O’Conner-Tressel, Tulan Do, Raymond J. Paxton, and J. David Beatty .......................... 846s

Uptake and Metabolism of $^{111}$In-labeled Monoclonal Antibody B6.2 by the Rat Liver.
Peter L. Jones, Beverly A. Brown, and Howard Sands .......................... 852s

Site-specifically Radioiodinated Antibody for Targeting Tumors.
Douglas W. Rea, Michiel E. Ullee, Benjamin A. Belinka, Jr., Daniel J. Coughlin, and Vernon L. Alvarez .......................... 857s

Radiolocalization of Monoclonal Antibodies in Hepatic Metastases from Human Colon Cancer in Congenitally Athymic Mice.
Kazuhiko Yoshida, Michel Rivoire, Chaitsaya Divgi, Sydney Welt, Alfred M. Cohen, and Elin R. Sigurdson .......................... 862s

Monoclonal Antibody Targeting of Human Non-Small Cell Carcinoma of the Lung.
Rhona Stein, Robert M. Sharkey, and David M. Goldenberg .......................... 866s

Carcinoembryonic Antigen and α-Fetoprotein Expression and Monoclonal Antibody Targeting in a Human Hepatoma/ Nodular Mouse Model.
Zhifu F. Wang, Rhona Stein, Robert M. Sharkey, and David M. Goldenberg .......................... 869s

Comparative Pharmacokinetics of a Murine Monoclonal Antibody to a Rat Colon Tumor in Rats and Nude Mice.
Jorge Laborda, Jean-Yves Douillard, Elaine F. Lizzo, and Thomas Hoffman .......................... 873s

Radioimmunodetection of Hepatic Metastases from Human Colon Cancer in Nude Mice with a Gamma-detecting Probe.
Michel Rivoire, Kazuhiko Yoshida, Chaitsaya Divgi, Sydney Welt, Alfred Cohen, and Elin R. Sigurdson .......................... 877s

Patterns of Antigen Distribution in Human Carcinomas.
M. Jules Mattes, Pierre P. Major, David M. Goldenberg, Arnold S. Dion, Robert V. P. Hutter, and Kenneth M. Klein .......................... 880s

Use of Whole-Body Autoradiography in Cancer Targeting with Radiolabeled Antibodies.
Irwin Fand, Robert M. Sharkey, and David M. Goldenberg .......................... 885s

SESSION III

Clinical Studies of Radioimmunodetection

Chairpersons: Steven M. Larson and Abass Alavi

Steven M. Larson .......................... 892s

Tumor Immunoscintigraphy by Means of Radiolabeled Monoclonal Antibodies: Multicenter Studies of the Italian National Research Council—Special Project “Biomedical Engineering”.
Antonio G. Siccardi .......................... 899s

Radioimaging of Melanoma Using $^{99}$mTc-labeled Fab Fragment Reactive with a High Molecular Weight Melanoma Antigen.
Lamk M. Lamki, Alexander A. Zukowski, L. Joy Shanken, Sewa S. Legha, Robert S. Benjamin, Carl E. Plager, Darrell F. Salk, Robert W. Schroff, and James L. Murray .......................... 904s

Clinical Studies of Cancer Radioimmunodetection with Carcinoembryonic Antigen Monoclonal Antibody Fragments Labeled with $^{125}$I or $^{99}$mTc.
David M. Goldenberg, Hildegard Goldenberg, Robert M. Sharkey, Edith Higginbotham-Ford, Robert E. Lee, Lawrence C. Swayne, Karen A. Burger, Diane Tsai, Jo Ann Horowitz, Thomas C. Hall, Carl M. Pinsky, and Hans J. Hansen .......................... 909s

Presurgical Imaging with Indium-labeled Anti-Carcinoembryonic Antigen for Colon Cancer Staging.
J. David Beatty, Lawrence E. Williams, David Yamauchi, Blaine A. Morton, L. Robert Hill, Barbara G. Beatty, Raymond J. Paxton, Bruce Merchant, and John E. Shively .......................... 922s

Breast Tumor Radioimmunodetection with a $^{111}$In-labeled Monoclonal Antibody (MAS) against a Mucin-like Antigen.
Pierre P. Major, Arnold S. Dion, Charlene J. Williams, M. Jules Mattes, Taqui Wang, and Leonard Rothenhall .......................... 927s

Human Biodistribution of $^{111}$In-labeled B72.3 Monoclonal Antibody.
Steven J. Harwood, Robert G. Carroll, William B. Webster, Linda M. Zangara, David L. Laven, Michele A. Morrissey, and Barbara J. Sini .......................... 932s

Immunolymphoscintigraphy and Immunoscintigraphy of Ovarian and Fallopian Tube Cancer Using F(ab$^\prime$)2 Fragments of Monoclonal Antibody OC 125.
Pentti Lehtovirta, Kalevi J. A. Kairemo, Kristian Liewendahl, and Markku Seppälä .......................... 937s

Lymphoscintigraphy in Melanoma: Initial Evaluation of a Low Protein Dose Monoclonal Antibody Cocktail.
Richard L. Wahl, Monica Liebert, John Headington, Barry S. Wilson, Barry L. Shulkin, Jon W. Johnson, Shirley Mallette, Ronald B. Natale, William Coon, Mary East, Robertson Davenport, M. B. Brown, John T. Niederhuber, and Neil A. Swanson .......................... 941s

Immunolymphoscintigraphy with $^{99}$mTc-labeled Monoclonal Antibody (BW 431/26) Reacting with Carcinoembryonic Antigen in Breast Cancer.
Kalevi J. A. Kairemo .......................... 949s
Radioimmunodetection in Rhabdo- and Leiomyosarcoma with 111In-Anti-Myosin Monoclonal Antibody Complex.
  André Planting, Jaap Verweij, Peter Cox, Mike Pillay, and Gerrit Stoter ........................................... 955s

Detection of Thrombophlebitis with 111In-labeled Anti-Fibrin Antibody: Preliminary Results.
  Abass Alavi, Naresh Gupta, Harold I. Palevsky, Mark A. Kelley, Allison D. Jatlow, Ann A. Byar, and Harvey J.
  Berger ................................................................. 958s

SESSION IV

Prospects for Therapy, I: Experimental

Chairperson: Mette Strand

  David A. Scheinberg and Mette Strand ........................................................................................................... 962s

Biological Considerations for Radioimmunotherapy.
  Robert M. Sharkey, Rosalyn D. Blumenthal, Hans J. Hansen, and David M. Goldenberg ............................ 964s

Current Status of Animal Radioimmunotherapy.
  Barry W. Wessels ............................................................................................................................................ 970s

Targeting and Therapy of Human Glioma Xenografts in Vivo Utilizing Radiolabeled Antibodies.
  Jeffery A. Williams, Barry W. Wessels, James A. Edwards, Kenneth A. Kopfer, Philip M. Wanek, Moody D.
  Wharam, Stanley E. Order, and Jerry L. Klein ............................................................................................... 974s

Imaging and Therapy of Small Cell Carcinoma Xenografts Using 131I-labeled Monoclonal Antibody SWA11.
  Alan Smith, Peter Groscurth, Robert Waibel, Gerrit Westera, and Rolf A. Stahel ................................. 980s

Radioimmunotherapy of Peritoneal Human Colon Cancer Xenografts with Site-specifically Modified 212Bi-labeled
  Antibody.
  R. Bruce Simonson, Michiel E. Ultee, Jo A. Hauler, and Vernon L. Alvarez ............................................. 985s

Radioimmunotherapy of Human Colon Carcinoma Xenograft with 90Y-ZCE025 Monoclonal Antibody: Toxicity
  and Tumor Phenotype Studies.
  Jose M. Estebaran, David M. Hyams, Barbara G. Beatty, Bruce Merchant, and J. David Beatty ..................... 989s

Comparative Binding and Preclinical Localization and Therapy Studies with Radiolabeled Human Chimeric and Murine
  17-1A Monoclonal Antibodies.
  Donald J. Buchsbaum, Pamela G. Brubaker, David E. Hanna, Arthur A. Glatfelter, Valeri H. Terry, Dianne M.
  Guilhaum, and Zenon Steplewski .................................................................................................................. 993s

Tumor Spheroid Model for the Biologically Targeted Radiotherapy of Neuroblastoma Micrometastases.
  K. A. Walker, R. Mairs, T. Murray, T. E. Hilditch, T. E. Wheldon, A. Gregor, and I. M. Hann .................... 1000s

Use of Hematopoietic Growth Factors to Control Myelosuppression Caused by Radioimmunotherapy.
  R. D. Blumenthal, R. M. Sharkey, L. M. Quinn, and D. M. Goldenberg ...................................................... 1003s

ROLE OF BONE MARROW TRANSPLANTATION IN 90Y ANTIBODY THERAPY OF COLON CANCER XENOGRaFTS IN Nude MICE.
  Blaine A. Morton, Barbara G. Beatty, Angeles P. Mison, Philip M. Wanek, and J. David Beatty ..................... 1008s

SESSION V

Prospects for Therapy, II: Clinical

Chairperson: Stanley E. Order

Radiolabeled Antibodies: Results and Potential in Cancer Therapy.
  S. E. Order, A. M. Sleeper, G. B. Stillwagon, J. L. Klein, and P. K. Leichner .................................................. 1011s

Fractionated Radioimmunotherapy of B-Cell Malignancies with ¹³¹I-Lym-1.
  Gerald L. DeNardo, Sally J. DeNardo, Lois F. O’Grady, Norman B. Levy, Gregory P. Adams, and Stanley L.
  Mills ................................................................................................................................................................. 1014s

High Dose Radiolabeled Antibody Therapy of Lymphoma.
  Irwin D. Bernstein, Janet F. Eary, Christopher C. Badger, Oliver W. Press, Fredrick R. Appelbaum, Paul J. Martin,
  Kenneth A. Krohn, Wil B. Nelp, Bruce Porter, Darrell Fisher, Richard Miller, Sherrie Brown, Ronald Levy, and
  E. Donnall Thomas ....................................................................................................................................... 1017s

Radioimmunotherapy of Human B-Cell Lymphoma with 90Y-conjugated Antidiotype Monoclonal Antibody.
  Barbara A. Parker, Artemios B. Vassos, Samuel E. Halpern, Richard A. Miller, Homer Hupf, Diane G. Amox,
  Joseph L. Simon, Robin J. Starr, Mark R. Green, and Ivor Royston ................................................................ 1022s

Estimation of Monoclonal Antibody-associated 90Y Activity Needed to Achieve Certain Tumor Radiation Doses in
  Colorectal Cancer Patients.
  Lawrence E. Williams, Barbara G. Beatty, J. David Beatty, Jeffrey Y. C. Wong, Raymond J. Paxton, and John E.
  Shively ......................................................................................................................................................... 1029s

Intraperitoneal Immunoconjugates.
  Thomas W. Griffin, Jeffrey Collins, Faran Bokhari, Mark Stochl, A. Bertrand Brill, Tsunao Ito, Georgette Emond,
  and Howard Sands ........................................................................................................................................ 1031s
Tumor, Red Marrow, and Organ Dosimetry for $^{131}I$-labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody.
Jeffry A. Siegel, David A. Pawlyk, Robert E. Lee, Norma L. Sasso, Jo Ann Horowitz, Robert M. Sharkey, and David M. Goldenberg ................................. 1039s
Dosimetric Model for Antibody Targeted Radionuclide Therapy of Tumor Cells in Cerebrospinal Fluid.
W. T. Millar and A. Barrett ................................................................. 1043s

SESSION VI
Host Responses and Complications

Chairperson: Thomas Hoffman
Anticipating, Recognizing, and Preventing Hazards Associated with in Vivo Use of Monoclonal Antibodies: Special Considerations Related to Human Anti-Mouse Antibodies.
Thomas Hoffman ................................................................. 1049s
Herve M. Blottière, J. Y. Douillard, H. Koprowski, and Z. Steplewski ................................................................. 1051s
Human Immune Response to Anti-Carcinoembryonic Antigen Murine Monoclonal Antibodies.
Michele J. Losman, Robert L. DeJager, Marc Monestier, Robert M. Sharkey, and David M. Goldenberg ................................................................. 1055s

Author Index ................................................................. 1059s

COVER LEGEND

Pictured are five of the scientists who made critical contributions to the development of radioimmuno- detection and radioimmunotherapy. Phil Gold (far left), codiscoverer of carcinoembryonic antigen, which has served as the prototype cancer marker and target for labeled antibodies, is currently Physician-in-Chief, Montreal General Hospital, Montreal, Canada. David Pressman (second from left), deceased, is credited with having made the early and seminal observations of organ and cancer targeting with antibodies against rodent tumors. David M. Goldenberg (center), who is President of the Center for Molecular Medicine and Immunology, Newark, New Jersey, organized the first and second conferences and provided the first demonstration in animals and humans of cancer imaging with radiolabeled antibodies against carcinoembryonic antigen, as well as a number of other cancer markers. William F. Bale (second from right), deceased, also was an early pioneer of animal studies of tumor localization with radiolabeled antibodies and pursued fibrin clot imaging and tumor therapy with radiolabeled anti-fibrin antibodies. Stanley E. Order (far right), who was one of the first proponents and innovators of radioimmunotherapy, is currently Professor and Director of Radiation Oncology, Johns Hopkins Cancer Center, Baltimore, Maryland. This photograph was made at the UICC Workshop on Radioimmunodetection of Cancer, Lexington, Kentucky, July 19–21, 1979.

The publication of the first conference held on the subject of cancer imaging and therapy with radiolabeled antibodies appeared as a supplement to the August 1980 issue of Cancer Research and has served as a frequently cited reference for the past 10 years.